Search Results - "Mrózek, E."

Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients by Mrózek, E., Rhoades, C. A., Allen, J., Hade, E. M., Shapiro, C. L.

“…Background:: We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of non-pegylated liposome-encapsulated doxorubicin (Myocet™;…”
Get full text

Yoga's Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial by KIECOLT-GLASER, Janice K, BENNETT, Jeanette M, ANDRIDGE, Rebecca, JUAN PENG, SHAPIRO, Charles L, MALARKEY, William B, EMERY, Charles F, LAYMAN, Rachel, MROZEK, Ewa E, GLASER, Ronald

“…To evaluate yoga's impact on inflammation, mood, and fatigue. A randomized controlled 3-month trial was conducted with two post-treatment assessments of 200…”
Get full text

Breast cancer and aging: results of the U13 conference breast cancer panel by Barginear, M. F., Muss, H., Kimmick, G., Owusu, C., Mrozek, E., Shahrokni, A., Ballman, K., Hurria, A.

“…Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the persisting misalignment between the age distribution of women…”
Get full text

Locoregional Failure Rates Are Low After Mastectomy in a Modern Cohort of Patients With T1-T2 Tumors With 1-3 Pathologically Involved Lymph Nodes by Bazan, J.G, Majithia, L, Quick, A.M, Terando, A.M, Agnese, D.M, Mrozek, E, Farrar, W, White, J.R

Get full text

Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells by MROZEK, E, ANDERSON, P, CALIGIURI, M. A

“…Human natural killer (NK) cells are bone marrow (BM)-derived CD2+CD16+CD56+ large granular lymphocytes (LGL) that lack CD3 yet contain the T-cell receptor…”
Get full text

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC) by Mrozek, E., Kolesar, J., Young, D., Allen, J., Villalona-Calero, M., Shapiro, C.L.

“…Preclinical studies show that mitomycin-C (MMC) followed by irinotecan (CPT-11) is synergistic. Therefore, we evaluated the toxicity and efficacy of…”
Get full text

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy by Fehniger, T A, Bluman, E M, Porter, M M, Mrózek, E, Cooper, M A, VanDeusen, J B, Frankel, S R, Stock, W, Caligiuri, M A

“…The continuous, in vivo infusion of low-dose IL-2 selectively expands the absolute number of human natural killer (NK) cells after 4-6 weeks of therapy. The…”
Get full text

Trisomy of chromosome 12 in a case of thecoma of the ovary by Mrózek, K, Nedoszytko, B, Babińska, M, Mrózek, E, Hrabowska, M, Emerich, J, Limon, J

“…Cytogenetic analysis was performed after short-term tissue culture of a thecoma of the ovary. Trisomy of chromosome 12 was revealed as the sole chromosome…”
Get more information

Stem Cell Factor Enhances Interleukin-2–Mediated Expansion of Murine Natural Killer Cells In Vivo by Fehniger, Todd A., Carson, William E., Mrózek, Ewa, Caligiuri, Michael A.

“…The administration of low dose interleukin-2 (IL-2) results in a selective expansion of natural killer (NK) cells in vivo, and promotes the differentiation of…”
Get full text

Abstract P3-12-01: Locoregional failure rates do not vary by breast cancer subtype after mastectomy in a modern cohort of patients with T1-2 tumors with 1-3 pathologically involved lymph nodes by Bazan, JG, Majithia, L, Quick, AM, Terando, AM, Agnese, D, Mrozek, E, Farrar, W, White, JR

“…Abstract Purpose/Objective(s): A recent meta-analysis of 22 randomized trials accrued between 1964-86 demonstrated significantly higher rates of locoregional…”
Get full text

Abstract P4-09-18: Characterization of circulating myeloid derived suppressor cells and cytokines in patients undergoing neo-adjuvant chemotherapy for breast cancer by Wesolowski, R, Duggan, M, Stiff, A, Trikha, P, Schoenfield, L, Abdel-Rasoul, M, Layman, R, Ramaswamy, B, Macrae, E, Lustberg, MB, Mrozek, E, Carson, WE

“…Abstract Myeloid derived suppressor cells (MDSC) are immature immune cells that expand in patients (pts) with cancer and suppress anti-tumor immunity. MDSC are…”
Get full text

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review by Poi, Ming J., Berger, Michael, Lustberg, Maryam, Layman, Rachel, Shapiro, Charles L., Ramaswamy, Bhuvaneswari, Mrozek, Ewa, Olson, Erin, Wesolowski, Robert

“…Purpose As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to…”
Get full text

Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma by Chatterjee, M, Mrozek, E, Vaickus, L, Oseroff, A, Stoll, H, Russell, D, Kohler, H, Foon, K A

Get more information

Anti-idiotype antibodies as potential therapeutic agents for human breast cancer by Bhattacharya-Chatterjee, M, Mrozek, E, Mukerjee, S, Ceriani, R L, Kohler, H, Foon, K A

Get more information

PD10-01: Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer by Ramaswamy, B, Srividya, V, Mullins, DA, Carothers, S, Young, G, Wenrui, D, Zhao, W, Lustberg, M, Leon, M, Weslowski, R, Layman, R, Mrozek, E, Shapiro, CL, Villalona-Calero, M

“…Abstract Purpose: BRCA1/2 deficient breast tumors are highly sensitive to poly- ADP-ribose polymerase inhibitors (PARPi). The Fanconi Anemia (FA) associated…”
Get full text

Abstract P2-11-07: Endothelial progenitor cells as novel markers of anthracycline induced cardiac injury by Lustberg, MB, Ruppert, AS, Carothers, S, Bingman, A, McCarthy, B, Raman, S, Das, M, Kanji, S, Lu, J, Das, H, Cinar-Akakin, H, Gurcan, MN, Berger, MJ, Wesolowski, R, Olson, EM, Ramaswamy, B, Mrozek, E, Layman, RM, Binkley, P, Shapiro, CL

“…Abstract Background: Anthracyclines including doxorubicin (DOX) cause myocardial damage that manifests as either subclinical decrements of left ventricular…”
Get full text

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant by Mrozek, E, Schaaf, LJ, Ramaswamy, B, Shiels, D, Houton, L, Shapiro, CL

“…Abstract Abstract #6131 Background: Treatment options for postmenopausal women (PW) with hormone responsive breast cancer (HRBC) involve blocking estrogen…”
Get full text

Nurses' attitudes toward pain, pain assessment, and pain management practices in long-term care facilities by Mrozek, Jane E., Werner, Joan Stehle

“…This descriptive study was designed to identify attitudes regarding pain as well as pain assessment and management practices of nurses working with elderly…”
Get full text

EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC) by Lustberg, M. B., Balasubramanian, P., Miller, B., Garcia Villa, A., Carothers, S., Michael, B., Mrozek, E., Ramaswamy, B., Layman, R. M., Wesolowski, R., Shapiro, C. L., Chalmers, J. J.

“…Abstract only…”
Get full text

Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI) by Mrozek, E., Lustberg, M. B., Knopp, M. V., Spigos, D. G., Yang, X., Houton, L. A., Ramaswamy, B., Layman, R. M., Povoski, S. P., Agnese, D. M.

“…Abstract only…”
Get full text